JULIANA PEREIRA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
12 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 12
bookPart Fatores de crescimento(2013) CHAMONE, Dalton de Alencar; DORLHIAC-LLACER, Pedro Henrique; PEREIRA, Juliana- Splenic Diffuse Red Pulp Small B Cell Lymphoma: Transformation To Diffuse Large Cells B Lymphoma(2013) BEZERRA, Evandro Dantas; FONTENELE, Leila Patricia; PEREIRA, Juliana; LAGE, Luis Alberto de Padua Covas; MACIEL, Felipe; BARQUINERO, Leticia; CARVALHO, Priscila R.; SIQUEIRA, Scheila; VELLOSO, Elvira R. P.
conferenceObject FREQUENCY OF LYMPHOMAS IN A COHORT OF PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY(2013) SINI, B. C.; KOKRON, C. M.; LEVY, D.; PEREIRA, Juliana; OLIVEIRA, Ana Karolina Barreto; COHON, Andrea; KALIL, Jorge; BYDLOWSKI, S. P.; BARROS, Myrthes ToledoIntroduction: Common variable immunodeficiency (CVID) is characterized by recurrent infections and in-creased susceptibility to autoimmunity and malignancies. Objective: To evaluate the frequency of lymphoma in a cohort of patients with CVID. Methods: Analysis of data obtained from medical records. Results: We analyzed 144 patients, 80 men and 64 women, aged 15-72 years. Seven (0.5 %) lymphoma cases were diagnosed (1 Hodgkin lymphoma and 6 non-Hodgkin lymphomas), affecting 5 men and 2 women aged 1953 years at lymphoma diagnosis. The time period between the onset of symptoms of CVID and lymphoma diagnosis ranged from 7 to 24 years in 4 patients and in 3 of them the diagnosis of both diseases were nearly overlapped preceding the CVID diagnosis in only 1, 3 and 6 months. Fever, splenomegaly and lymphadenopathy occurred in all patients. Lymphocytosis with inversion of the CD4/CD8 ratio at the expense of increased CD8+ T cells was detected in 2 patients and lymphopenia in one. B lymphocytes were undetectable in 3 patients in whom the diagnosis of lymphoma and CVID were established simultaneously and in one B cells were present at the beginning of CVID but undetectable at diagnosis of lymphoma. Conclusions: Patients with absence of B cells in recently diagnosed CVID or absence of B cells in long term followed CVID with previously detectable B cells demands a screening for the presence of lymphomas.conferenceObject ASSESSMENT OF LABILE PLASMA IRON IN PATIENTS SUBMITTED TO HEMATOPOIETIC STEM CELL TRANSPLANTATION(2013) NAOUM, Flavio; ESPOSITO, Breno; RUIZ, Lilian; RUIZ, Milton; TANAKA, Paula; PEREIRA, Juliana; CANCADO, Rodolfo; BARROS, Jose- Azidothymidine is Effective Against Human Multiple Myeloma: A New Use for an Old Drug?(2013) PEREIRA, Juliana; LEVY, Debora; RUIZ, Jorge L. M.; BROCARDO, Graciela A.; FERREIRA, Kleber A.; COSTA, Renata O.; QUEIROZ, Rodrigo G.; MARIA, Durvanei A.; HALLACK NETO, Abrahao E.; CHAMONE, Dalton A. F.; BYDLOWSKI, Sergio P.Azidothymidine (AZT) is an antiretroviral drug that affects cell proliferation, apoptosis, and the NF-kappa B pathway. As multiple myeloma (MM) presents with constitutive activation of NF-kappa B, we analyzed the effect of AZT on human MM cell lines. We evaluated the cytotoxic effect of AZT in human MM cell lines sensitive (8226/S) or resistant to doxorubicin (8226/DX5) and human T cell lymphoblast-like cells, uterine sarcoma cells, and HUVEC using MTT assay. Cytotoxicity was also evaluated in vivo in nude mice xenografted with 8226/S tumor. The effect of AZT on the expression of genes involved in cell proliferation, apoptosis, angiogenesis, and the NF-kappa B pathway was analyzed in the xenografts using real-time polymerase chain reaction. AZT was effective against both 8226/S and 8226/DX5 cells in a dose and time-dependent manner (p = 0.02) in vitro and promoted cell cycle arrest in S phase in these cells. The tumor volume was lower in mice treated with AZT compared to untreated mice (p = 0.0003). AZT down-regulated the pro-proliferative genes encoding AKT1, MYC, STAT1, MAPK8, MAPK9, CCL-3, Bcl-3, and cyclin D2; pro-angiogenenic genes encoding VEGF and IL8; and genes involved in cell adhesion (ICAM1 and FN1) and the NF-kappa B pathway. AZT up-regulated the expression of tumor suppressor gene FOXP1 and the pro-apoptotic genes encoding BID, Bcl-10, and caspase-8. Thus, we demonstrated the cytotoxic effect of AZT in human MM cell lines for the first time. Our data may provide the rationale for future clinical trials of AZT for treating MM.
bookPart Linfomas(2013) PEREIRA, Juliana; COSTA, Renata Oliveira; HALLACK NETO, Abrahão Elias- Would Be Cyclophosphamide, Thalidomide and Dexamethasone (CTD) a Possible Treatment For Multiple Myeloma Where Is Not Possible New Drugs?(2013) BELLESSO, Marcelo; SILVA, Marcela Cavalcante de Andrade; VELASQUES, Rodrigo Dolphini; VISNADI, Helena; SHCOLNIK, Roberta; SEGURO, Fernanda Salles; LEVY, Debora; ABDO, Andre Neder Ramires; SANTUCCI, Rodrigo; PEREIRA, Juliana; MARTINEZ, Gracia Aparecida
conferenceObject PROGNOSTIC IMPACT OF THE LYMPH NODE METASTATIC RATIO IN 5-YEAR SURVIVAL OF PATIENTS WITH RECTAL CANCER NOT SUBMITTED TO PREOPERATIVE CHEMORADIATION.(2013) MARTINEZ, C. Real; JACOMO, A.; AKAMATSU, F.; PEREIRA, J.; NONOSE, R.; SATO, D.; RODRIGUES, M.- Infection Related to Implantable Central Venous Access Devices in Cancer Patients: Epidemiology and Risk Factors(2013) FREIRE, Maristela P.; PIERROTTI, Ligia C.; ZERATI, Antonio E.; ARAUJO, Pedro H. X. N.; MOTTA-LEAL-FILHO, J. M.; DUARTE, Laiane P. G.; IBRAHIM, Karim Y.; SOUZA, Antonia A. L.; DIZ, Maria P. E.; PEREIRA, Juliana; HOFF, Paulo M.; ABDALA, EdsonOBJECTIVE. To describe the epidemiology of infections related to the use of implantable central venous access devices (CVADs) in cancer patients and to evaluate measures aimed at reducing the rates of such infections. DESIGN. Prospective cohort study. SETTING. Referral hospital for cancer in Sao Paulo, Brazil. PATIENTS. We prospectively evaluated all implantable CVADs employed between January 2009 and December 2011. Inpatients and outpatients were followed until catheter removal, transfer to another facility, or death. METHODS. Outcome measures were bloodstream infection and pocket infection. We also evaluated the effects that the creation of a multidisciplinary team for CVAD care, avoiding in-hospital implantation of CVADs, and limiting CVAD insertion in neutropenic patients have on the rates of such infections. RESULTS. During the study period, 966 CVADs (mostly venous ports) were implanted in 933 patients, for a combined total of 243,792 catheter-days. We identified 184 episodes of infection: 154 (84%) were bloodstream infections, 21 (11%) were pocket infections, and 9 (5%) were surgical site infections. During the study period, the rate of CVAD-related infection dropped from 2.2 to 0.24 per 1,000 catheter-days (P < .001). Multivariate analysis revealed that relevant risk factors for such infection include surgical reintervention, implantation in a neutropenic patient, in-hospital implantation, use of a cuffed catheter, and nonchemotherapy indication for catheter use. CONCLUSIONS. Establishing a multidisciplinary team specifically focused on CVAD care, together with systematic reporting of infections, appears to reduce the rates of infection related to the use of these devices.
bookPart Leucemia linfonoide crônica(2013) PEREIRA, Juliana; COSTA, Renata de Oliveira